<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01288131</url>
  </required_header>
  <id_info>
    <org_study_id>2011/01_Medicine</org_study_id>
    <nct_id>NCT01288131</nct_id>
  </id_info>
  <brief_title>Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment</brief_title>
  <official_title>Randomized Controlled Trial Study of Anti-r-HuEpo Associated PRCA Treated by Cyclosporine and Mycophenolate Mofetil (MMF) Compared With Cyclophosphamide and Prednisolone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recombinant human erythropoietin (r-HuEpo) has been used to treat renal anemia and improve
      morbidity and mortality in chronic kidney disease. Subcutaneous use of r-HuEpo causes
      immunogenicity and develops anti-r-HuEpo associated pure red cell aplasia (PRCA). The
      treatment of anti-r-HuEpo associated pure red cell aplasia is controversial. The
      investigators aim to evaluate the treatment for anti-r-HuEpo associated pure red cell aplasia
      in this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recombinant human erythropoietin was the first biotherapeutic medicinal product derived from
      recombinant DNA technology for the treatment of anemia in patients with chronic kidney
      disease (CKD). Although r-HuEpo raises hemoglobin levels in CKD and improves morbidity
      associated with anemia in CKD patients, the adverse immunological effect of r-HuEpo
      administered subcutaneously can result in anti-r-HuEpo associated PRCA. We aim to evaluate
      the effectiveness of two treatment protocol, cyclosporine combined with mycophenolate mofetil
      and cyclophosphamide combined with prednisolone for treatment of anti-r-HuEpo associated
      PRCA.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    We observed &gt;90 % efficacy in cyclophosphamide and Prednisolone group for treatment of
    anti-i-HuEpo associated PRCA
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>anti-r-HuEpo antibody</measure>
    <time_frame>Day 0 and month 6</time_frame>
    <description>The anti-r-HuEpo antibody titer at day 0 (before treatment) and month 6 (6th month after treatment) of each arm will be compared</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute reticulocyte count</measure>
    <time_frame>Day 0 and month 6</time_frame>
    <description>The Absolute reticulocyte count at day 0 (before treatment) and month 6 (6th month after treatment) of each arm will be compared</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Anti-r-HuEpo Associated PRCA Subjects</condition>
  <arm_group>
    <arm_group_label>CSA+MMF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclosporine 100 mg BID combine with Mycophenolate mofetil 750 mg BID for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide + pred</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclophosphamide 100 mg QD and prednisolone 1.0 mg/kg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine combine with mycophenolate mofetil</intervention_name>
    <description>Cyclosporine 100 mg BID and mycophenolate mofetil 750 mg BID for 24 weeks</description>
    <arm_group_label>CSA+MMF</arm_group_label>
    <other_name>Neoral</other_name>
    <other_name>Cellcept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide + pred</intervention_name>
    <description>Cyclophosphamide 100 mg QD combine with prednisolon 1.0 mg/kg/day</description>
    <arm_group_label>Cyclophosphamide + pred</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age more than 18 years old

          -  CKD patient with anti-r-huEpo associated PRCA

        Exclusion Criteria:

          -  Pregnancy or lactating women

          -  Receiving immunosuppression

          -  Active infection

          -  Previous history of allergic reaction to cyclosporine, mycophenolate mofetil,
             cyclophosphamide, prednisolone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kearkiat Praditpornsilpa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kearkiat Praditpornsilpa</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2011</study_first_submitted>
  <study_first_submitted_qc>February 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2011</study_first_posted>
  <last_update_submitted>January 27, 2014</last_update_submitted>
  <last_update_submitted_qc>January 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Kearkiat Praditpornsilpa</investigator_full_name>
    <investigator_title>Associted Professor</investigator_title>
  </responsible_party>
  <keyword>Anti-r-HuEpo antibody</keyword>
  <keyword>Anti-r-HuEpo associated PRCA</keyword>
  <keyword>Treatment</keyword>
  <keyword>Absolute reticulocyte count</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

